Celecoxib effectivness and tolerance in out-patient's department practice;Efficacia e tollerabilità del celecoxib nella pratica clinica ambulatoriale

Clinica Terapeutica

Volumn 154, Issue 1, 2003, Pages 17-20

  Cancilleri, Francesco ^a   Caione, G ^a   Di Martino, A ^a   Marinozzi, A ^a   Stellato, G M F ^a   Denaro, V ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Articular pain; Celecoxib; NSAID

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; HUMAN; INFLAMMATION; OSTEOARTHRITIS; OUTPATIENT; PAIN; RHEUMATOID ARTHRITIS; SIDE EFFECT; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; OUTPATIENTS; PAIN MEASUREMENT; PYRAZOLES; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TIME FACTORS;

EID: 0037799378     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schmassmann A, Peskar BM, Stettler C, et al.: Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rat. Br J Pharmacol 123: 795-804, 1998
2. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcer associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced-ulcer-menagement (OMNIUM) Study Group. N Engl J Med 338: 727-734, 1998
3. Reuter BK, Asfaha S, Buret A, et al.: Exacerbation of inflammation-associated colonic injury in rat through inhibition of cycloossigenase-2. J Clin Invest 98: 2076-2085, 1996
4. Crofford LJ, Lipsky PE, Brooks P, et al.: Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum 43: 4-13, 2000
5. Crofford LJ, Oates JC, McCune WJ, et al.: Thrombosis in patients with connective tissue disease treated with specific ciclooxigenase 2 inhibitors. Arthritis Rheum 43: 1891-1896, 2000
6. DuBois RN: Cyclooxigenase in biology and disease. FASEB J 12: 1063-1073, 1998
7. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995
8. Tsujii M, Kawano S, Tsuji S, et al.: Cyclooxigenase regulated angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998
9. Forwood MR: Inducible cyclo-oxigenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11: 1688-1693, 1996
10. Ermert L, Ermert M, Goppelt-Struebe M, et al.: Cyclo-oxigenase isoenzyme localization and mRNA expression in rat lung. Am J Respir Cell Mol Biol 18: 479-488, 1998
11. Bishop-Beiley D: Induction of cyclooxigenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 17: 1644-1648, 1997
12. Mc Adams BF, Catella LF, Mardini IA, et al.: Systhematic biosynthesis of prostacyclin by cyclooxigenase (COX)-2: the human pharmacology of selective inhibitors of COX-2. Proc Natl Acad Sci-USA 96: 272-277, 1999
13. Wallace JL: Distribution of expression of cyclooxigenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAID). Am J Med 107: 11S-16S, 1999
14. Simon LS, Lanza FL, Lipsky PE, et al.: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxigenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41: 1591-1602, 1998